Victory Capital Management
ADAP

Victory Capital Management’s Adaptimmune Therapeutics ADAP Stock Holding History

Victory Capital Management’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2,922,819
Closed -$23.3M – 2536
2020
Q3 		$23.3M Buy
2,922,819
+1,006,439
+53% +$8.81M 0.03% 725
2020
Q2 		$19.2M Buy
+1,916,380
New +$12M 0.03% 801

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Victory Capital Management's ADAP Position: Q4 2020 in Review

Victory Capital Management sold out of Adaptimmune Therapeutics (ADAP) in Q4 2020, closing a stake of 2,922,819 shares — an estimated $23.3M sold.

Victory Capital Management first reported a position in ADAP in Q2 2020 and held it in 2 quarters. The position peaked at $23.3M in Q3 2020. 87 funds tracked by Wall St. Rank hold ADAP as of Q4 2020.

  • Victory Capital Management reported no remaining Adaptimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Victory Capital Management sold 2,922,819 Adaptimmune Therapeutics shares in Q4 2020, an estimated $23.3M.
  • Victory Capital Management first reported a position in Adaptimmune Therapeutics in Q2 2020 and held it in 2 quarters.
  • Victory Capital Management's Adaptimmune Therapeutics position peaked at $23.3M in Q3 2020.
  • 87 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2020.

Based on Victory Capital Management's 13F filing for Q4 2020, filed 1 Feb 2021.